Aardvark Therapeutics
web2Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule m...
About
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines aimed at hunger-related pathways for metabolic diseases, including rare hyperphagia disorders and obesity. Its lead candidate, oral ARD-101, activates bitter taste receptors in the digestive tract and was studied for hyperphagia associated with Prader-Willi syndrome. The company has also described ARD-201, a proposed fixed-dose combination of ARD-101 and a DPP-4 inhibitor, for obesity-related conditions. In October 2026, Aardvark reported that its Phase 3 HERO and open-label extension trials had been terminated and that available efficacy findings were exploratory. The FDA lifted a clinical hold on ARD-101, but the candidate remains investigational and the announcement did not establish approval for commercial use.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
1 expert evaluated Aardvark Therapeutics.
Experts evaluating Aardvark Therapeutics
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy